Apolipoprotein B in cardiovascular risk assessment

被引：6
|
作者：
Ahmad, Maud [1 ]
Sniderman, Allan D. [2 ]
Hegele, Robert A. [1 ]
机构：
[1] Western Univ, Schulich Sch Med & Dent, London, ON, Canada
[2] McGill Univ, Hlth Ctr, Mike & Valeria Rosenbloom Ctr Cardiovasc Prevent, Dept Med, Montreal, PQ, Canada
来源：
CANADIAN MEDICAL ASSOCIATION JOURNAL | 2023年 / 195卷 / 33期
关键词：
D O I：
10.1503/cmaj.230048
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E1124 / E1124
页数：1
相关论文
共 50 条
  • [21] Cardiovascular disease risk associated with serum apolipoprotein B is modified by serum vitamin A
    Olsen, Thomas
    Vinknes, Kathrine J.
    Svingen, Gard F. T.
    Pedersen, Eva R.
    Tell, Grethe S.
    Blomhoff, Rune
    Drevon, Christian A.
    Ueland, Per M.
    Midttun, Oivind
    Refsum, Helga
    Nygard, Ottar K.
    ATHEROSCLEROSIS, 2017, 265 : 325 - 330
  • [22] Physiochemically modified apolipoprotein B-containing lipoproteins and the risk of cardiovascular disease
    Rosenson, R. S.
    JOURNAL OF INTERNAL MEDICINE, 2010, 268 (04) : 316 - 319
  • [23] Value of apolipoprotein B/A1 ratio in cardiovascular risk assessment; Case control analysis in EPIC-Norfolk study
    Boekholdt, S. M.
    Van Der Steeg, W. A.
    Stein, E. A.
    Stroes, E. S. G.
    Wareham, N. J.
    Jukema, J. W.
    Bingham, S. A.
    Zwinderman, A. H.
    Kastelein, J. J. P.
    Khaw, K. T.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 37 - 38
  • [24] Multiplexed apolipoprotein profiling advances the assessment of residual lipid-related cardiovascular risk
    Schmidt, L.
    Clarke, R.
    Von Ende, A.
    Yin, X.
    Theofilatos, K.
    Hopewell, J.
    Mayr, M.
    CARDIOVASCULAR RESEARCH, 2022, 118 (SUPPL 1)
  • [25] Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD
    Lamprea-Montealegre, Julio Alejandro
    Staplin, Natalie
    Herrington, William G.
    Haynes, Richard
    Emberson, Jonathan
    Baigent, Colin
    de Boer, Ian H.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (01): : 47 - 60
  • [26] Apolipoprotein B and risk of cardiovascular disease: A meta-analysis of randomized controlled trials
    Galimberti, Federica
    Catapano, Alberico L.
    Katzmann, Julius L.
    Cupido, Arjen J.
    Ference, Brian A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 53 - 53
  • [27] Lipoprotein(a) cardiovascular disease risk not captured by low density lipoprotein cholesterol and apolipoprotein B
    Thomas, P.
    Vedel-Krogh, S.
    Kamstrup, P. R.
    Nordestgaard, B. G.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [28] Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
    Hagstrom, Emil
    Steg, P. Gabriel
    Szarek, Michael
    Bhatt, Deepak L.
    Bittner, Vera A.
    Danchin, Nicolas
    Diaz, Rafael
    Goodman, Shaun G.
    Harrington, Robert A.
    Jukema, J. Wouter
    Liberopoulos, Evangelos
    Marx, Nikolaus
    McGinniss, Jennifer
    Manvelian, Garen
    Pordy, Robert
    Scemama, Michel
    White, Harvey D.
    Zeiher, Andreas M.
    Schwartz, Gregory G.
    CIRCULATION, 2022, 146 (09) : 657 - 672
  • [29] Integration of apolipoprotein B into the SCORE2 framework: implications for cardiovascular risk prediction
    Wong, Wen Kai
    Takeuchi, Fumihiko
    Thao, Le Thi Phuong
    Nicholls, Stephen J.
    Chew, Derek P.
    Peter, Karlheinz
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2025,
  • [30] Effect of Aerobic Exercise on Risk Factors of Cardiovascular Disease and the Apolipoprotein B/Apolipoprotein A-1 Ratio in Obese Woman
    Kim, Dae-Young
    Jung, Sun-Young
    JOURNAL OF PHYSICAL THERAPY SCIENCE, 2014, 26 (11) : 1825 - 1829
12345